Efficiency is the key for a good downstream process to obtain consistently a pure and high quality product while recovering as much target protein as possible. Celonic has set up a downstream platform process for antibodies, often recovering more than 75% of the target mAB. This saves considerable development time and costs.
In addition, our experience in process development for non-antibody products enables us to maximize the product recovery during platform adaptation.
- Adaption of state-of-the-art purification processes for mABs
- Process development for non-antibody products
- Process intermediate stability studies
- Virus clearance studies
- Extensive experience in purifying products from in-house CHOvolution™ and the human GEX® cell line